{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:00:30Z","timestamp":1793289630457,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with decompensated cirrhosis are at risk of developing acute kidney injury (AKI). Studies have suggested that inhibition of the Renin-Angiotensin System (RAS) has certain nephro- and hepatoprotective effects in patients with compensated liver disease. This study aimed to investigate the clinical impact of RAS-Inhibitors in individuals with decompensated liver cirrhosis. Overall, 1181 consecutive hospitalized patients with ascites that underwent paracentesis were considered for this retrospective study. In total, 667 patients with decompensated cirrhosis fulfilled the inclusion criteria and were finally analyzed. RAS-Inhibitor intake was documented in 41 patients (7%). First, 28-day incidences of AKI and grade III AKI of all patients with RAS-Inhibitors were compared to those without intake. Afterwards, propensity score matching was conducted in a 3:1 manner. Here, incidence of further renal endpoints such as need of hemodialysis were analyzed in detail. In the unmatched setting, intake of RAS-Inhibitors was not associated with an increased 28\u00a0day-incidence of AKI (P\u2009=\u20090.76) or LTx-free survival (P\u2009=\u20090.60). However, 28\u00a0day-incidence of grade III AKI was significantly lower in patients with RAS-Inhibitor intake (P\u2009&lt;\u20090.001). In the matched setting, 28\u00a0day-incidence of AKI did not differ (P\u2009=\u20090.81), while grade III AKI was significantly less frequent in the RAS-Inhibitor group (P\u2009&lt;\u20090.001). Need for hemodialysis was also significantly lower in patients with RAS-Inhibitors (P\u2009=\u20090.03) and LTx-free survival was comparable between both groups (P\u2009=\u20090.52). Thus, this study suggests that intake of RAS-Inhibitors is associated with decreased incidences of grade III AKI and need of hemodialysis in patients with decompensated liver disease.<\/jats:p>","DOI":"10.1038\/s41598-023-44299-w","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T19:01:16Z","timestamp":1697310076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of renin\u2013angiotensin inhibitors on renal function and the clinical course in patients with decompensated cirrhosis"],"prefix":"10.1038","volume":"13","author":[{"given":"Tammo L.","family":"Tergast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Griemsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Maasoumy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,14]]},"reference":[{"key":"44299_CR1","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","volume":"144","author":"R Moreau","year":"2013","unstructured":"Moreau, R. et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144, 1426\u20131437 (2013) (1437.e1).","journal-title":"Gastroenterology"},{"key":"44299_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/gutjnl-2014-308874","volume":"64","author":"P Angeli","year":"2015","unstructured":"Angeli, P. et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut 64, 531\u2013537 (2015).","journal-title":"Gut"},{"key":"44299_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-021-00284-z","volume":"7","author":"JA Kellum","year":"2021","unstructured":"Kellum, J. A. et al. Acute kidney injury. Nat. Rev. Dis. Primers. 7, 52 (2021).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"44299_CR4","first-page":"687","volume":"119","author":"B Schulte","year":"2022","unstructured":"Schulte, B. et al. Metamizole-associated risks in decompensated hepatic cirrhosis. Dtsch. Arztebl Int. 119, 687\u2013693 (2022).","journal-title":"Dtsch. Arztebl Int."},{"key":"44299_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41424-018-0053-0","volume":"9","author":"TL Tergast","year":"2018","unstructured":"Tergast, T. L. et al. Association between type 2 diabetes mellitus, HbA1c and the risk for spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis and ascites. Clin. Transl. Gastroenterol. 9, 189\u2013218 (2018).","journal-title":"Clin. Transl. Gastroenterol."},{"key":"44299_CR6","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","volume":"71","author":"FH Messerli","year":"2018","unstructured":"Messerli, F. H., Bangalore, S., Bavishi, C. & Rimoldi, S. F. Angiotensin-converting enzyme inhibitors in hypertension: To use or not to use?. J. Am. Coll. Cardiol. 71, 1474\u20131482 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"44299_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1053\/ajkd.2002.36340","volume":"40","author":"S Efrati","year":"2002","unstructured":"Efrati, S. et al. ACE inhibitors and survival of hemodialysis patients. Am. J. Kidney Dis. 40, 1023\u20131029 (2002).","journal-title":"Am. J. Kidney Dis."},{"key":"44299_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1177\/2050640617695698","volume":"5","author":"M Pinter","year":"2017","unstructured":"Pinter, M. et al. Use of inhibitors of the renin\u2013angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. United Eur. Gastroenterol. J. 5, 987\u2013996 (2017).","journal-title":"United Eur. Gastroenterol. J."},{"key":"44299_CR9","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1038\/s41598-021-81959-1","volume":"11","author":"KM Kim","year":"2021","unstructured":"Kim, K. M., Roh, J., Lee, S. & Yoon, J. Clinical implications of renin\u2013angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease. Sci. Rep. 11, 2884 (2021).","journal-title":"Sci. Rep."},{"key":"44299_CR10","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0016-5085(85)80088-3","volume":"88","author":"EA Pariente","year":"1985","unstructured":"Pariente, E. A., Bataille, C., Bercoff, E. & Lebrec, D. Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology 88, 1255\u20131259 (1985).","journal-title":"Gastroenterology"},{"key":"44299_CR11","unstructured":"European Association for the Study of the Liver Electronic address: easloffice@easloffice eu & European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. 69, 406\u2013460 (2018)."},{"key":"44299_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000060155","volume":"135","author":"A Toke","year":"2001","unstructured":"Toke, A. & Meyer, T. W. Hemodynamic effects of angiotensin II in the kidney. Contrib. Nephrol. 135, 34\u201346 (2001).","journal-title":"Contrib. Nephrol."},{"key":"44299_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1159\/000187513","volume":"65","author":"R Moreau","year":"1993","unstructured":"Moreau, R. et al. Renal hemodynamics in patients with cirrhosis: Relationship with ascites and liver failure. Nephron 65, 359\u2013363 (1993).","journal-title":"Nephron"},{"key":"44299_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/2050640620913732","volume":"8","author":"M Schultalbers","year":"2020","unstructured":"Schultalbers, M. et al. Frequency, characteristics and impact of multiple consecutive nosocomial infections in patients with decompensated liver cirrhosis and ascites. United Eur. Gastroenterol. J. 8, 567\u2013576 (2020).","journal-title":"United Eur. Gastroenterol. J."},{"key":"44299_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000475607","volume":"137","author":"SA Silver","year":"2017","unstructured":"Silver, S. A. & Chertow, G. M. The economic consequences of acute kidney injury. Nephron 137, 297\u2013301 (2017).","journal-title":"Nephron"},{"key":"44299_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/flgastro-2012-100291","volume":"4","author":"RA Scott","year":"2013","unstructured":"Scott, R. A., Austin, A. S., Kolhe, N. V., McIntyre, C. W. & Selby, N. M. Acute kidney injury is independently associated with death in patients with cirrhosis. Frontline Gastroenterol. 4, 191\u2013197 (2013).","journal-title":"Frontline Gastroenterol."},{"key":"44299_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/apt.17289","volume":"57","author":"TL Tergast","year":"2023","unstructured":"Tergast, T. L. et al. Application of CT contrast medium is not associated with an increased risk for acute kidney injury in patients with decompensated cirrhosis. Aliment. Pharmacol. Ther. 57, 136\u2013145 (2023).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"44299_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2174\/138161209787315747","volume":"15","author":"P Jankowski","year":"2009","unstructured":"Jankowski, P., Safar, M. & Benetos, A. Pleiotropic effects of drugs inhibiting the renin\u2013angiotensin\u2013aldosterone system. Curr. Pharm. Des. 15, 571\u2013584 (2009).","journal-title":"Curr. Pharm. Des."},{"key":"44299_CR19","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/liv.12611","volume":"35","author":"GB Goh","year":"2015","unstructured":"Goh, G. B. et al. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int. 35, 979\u2013985 (2015).","journal-title":"Liver Int."},{"key":"44299_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jhep.2010.03.013","volume":"53","author":"P Tandon","year":"2010","unstructured":"Tandon, P., Abraldes, J. G., Berzigotti, A., Garcia-Pagan, J. C. & Bosch, J. Renin\u2013angiotensin\u2013aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis. J. Hepatol. 53, 273\u2013282 (2010).","journal-title":"J. Hepatol."},{"key":"44299_CR21","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1097\/00005344-198900000-00006","volume":"14","author":"J Sraer","year":"1989","unstructured":"Sraer, J., Kanfer, A., Rondeau, E. & Lacave, R. Role of the renin\u2013angiotensin system in the regulation of glomerular filtration. J. Cardiovasc. Pharmacol. 14, S21\u2013S25 (1989).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"44299_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ki.2011.79","volume":"80","author":"FA Holtkamp","year":"2011","unstructured":"Holtkamp, F. A. et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 80, 282\u2013287 (2011).","journal-title":"Kidney Int."},{"key":"44299_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0895-7061(97)00420-2","volume":"11","author":"L Vaur","year":"1998","unstructured":"Vaur, L. et al. Short-term effects of withdrawing angiotensin converting enzyme inhibitor therapy on home self-measured blood pressure in hypertensive patients. Am. J. Hypertens. 11, 165\u2013173 (1998).","journal-title":"Am. J. Hypertens."},{"key":"44299_CR24","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.3390\/ijms23073915","volume":"23","author":"G Capolongo","year":"2022","unstructured":"Capolongo, G., Capasso, G. & Viggiano, D. A shared nephroprotective mechanism for renin-angiotensin-system inhibitors, sodium-glucose co-transporter 2 inhibitors, and vasopressin receptor antagonists: Immunology meets hemodynamics. Int. J. Mol. Sci. 23, 3915 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"44299_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2021.111254","volume":"529","author":"E Cantero-Navarro","year":"2021","unstructured":"Cantero-Navarro, E. et al. Renin\u2013angiotensin system and inflammation update. Mol. Cell. Endocrinol. 529, 111254 (2021).","journal-title":"Mol. Cell. Endocrinol."},{"key":"44299_CR26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/liv.14057","volume":"39","author":"CM Lange","year":"2019","unstructured":"Lange, C. M. Systemic inflammation in hepatorenal syndrome\u2013A target for novel treatment strategies?. Liver Int. 39, 1199\u20131201 (2019).","journal-title":"Liver Int."},{"key":"44299_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/157489007779606130","volume":"2","author":"D Skultetyova","year":"2007","unstructured":"Skultetyova, D., Filipova, S., Riecansky, I. & Skultety, J. The role of angiotensin type 1 receptor in inflammation and endothelial dysfunction. Recent Patents Cardiovasc. Drug Discov. (Discontinued) 2, 23\u201327 (2007).","journal-title":"Recent Patents Cardiovasc. Drug Discov. (Discontinued)"},{"key":"44299_CR28","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/jcp.22940","volume":"227","author":"LL Souza","year":"2012","unstructured":"Souza, L. L. & Costa-Neto, C. M. Angiotensin-(1\u20137) decreases LPS-induced inflammatory response in macrophages. J. Cell. Physiol. 227, 2117\u20132122 (2012).","journal-title":"J. Cell. Physiol."},{"key":"44299_CR29","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/hep.23421","volume":"51","author":"M Moreno","year":"2010","unstructured":"Moreno, M. et al. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 51, 942\u2013952 (2010).","journal-title":"Hepatology"},{"key":"44299_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/liv.14272","volume":"40","author":"G Sanso\u00e8","year":"2020","unstructured":"Sanso\u00e8, G., Aragno, M. & Wong, F. Pathways of hepatic and renal damage through non-classical activation of the renin\u2013angiotensin system in chronic liver disease. Liver Int. 40, 18\u201331 (2020).","journal-title":"Liver Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44299-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44299-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44299-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T23:34:37Z","timestamp":1700350477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44299-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["44299"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-44299-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,14]]},"assertion":[{"value":"25 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17486"}}